MIGUEL A GOICOECHEA

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
  2. ncbi Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients
    Miguel Goicoechea
    University California San Diego, San Diego, California, USA
    AIDS 24:707-16. 2010
  3. ncbi Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
    Miguel Goicoechea
    Antiviral Research Center, University of California, San Diego, 150 W Washington St, Ste 100, San Diego, CA 92103, USA
    J Infect Dis 197:102-8. 2008
  4. ncbi A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring
    Miguel Goicoechea
    University of California San Diego, San Diego, CA, USA
    Antivir Ther 12:55-62. 2007
  5. ncbi Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Miguel Goicoechea
    University California, School of Medicine, San Diego, CA 92103, USA
    Expert Opin Pharmacother 8:371-82. 2007
  6. ncbi Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA
    Miguel Goicoechea
    Department of Medicine, University of California, San Diego, Antiviral Antiviral Research Center, 92131
    J Infect Dis 194:29-37. 2006
  7. ncbi Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression
    Miguel Goicoechea
    University California San Diego, School of Medicine, San Diego, California 92103, USA
    AIDS Patient Care STDS 20:233-7. 2006
  8. ncbi A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
  9. ncbi Efavirenz--still first-line king?
    Brookie M Best
    University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093 0719, USA
    Expert Opin Drug Metab Toxicol 4:965-72. 2008
  10. ncbi Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery
    Christopher H Woelk
    Department of Medicine, University of California, San Diego, La Jolla, USA
    AIDS 24:217-22. 2010

Research Grants

  1. Pharmacokinetics and Pathogenesis of Treatment Responses
    Miguel Goicoechea; Fiscal Year: 2007

Detail Information

Publications10

  1. ncbi Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment
    Edward R Cachay
    Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
    AIDS Res Ther 8:29. 2011
    ..abstract:..
  2. ncbi Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients
    Miguel Goicoechea
    University California San Diego, San Diego, California, USA
    AIDS 24:707-16. 2010
    ..To evaluate a potential pharmacodynamic/pharmacokinetic interaction between abacavir (ABC) and tenofovir disoproxil fumarate (TDF)...
  3. ncbi Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
    Miguel Goicoechea
    Antiviral Research Center, University of California, San Diego, 150 W Washington St, Ste 100, San Diego, CA 92103, USA
    J Infect Dis 197:102-8. 2008
    ....
  4. ncbi A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring
    Miguel Goicoechea
    University of California San Diego, San Diego, CA, USA
    Antivir Ther 12:55-62. 2007
    ..To develop a computer-based system for modelling and interpreting plasma antiretroviral concentrations for therapeutic drug monitoring (TDM)...
  5. ncbi Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Miguel Goicoechea
    University California, School of Medicine, San Diego, CA 92103, USA
    Expert Opin Pharmacother 8:371-82. 2007
    ....
  6. ncbi Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA
    Miguel Goicoechea
    Department of Medicine, University of California, San Diego, Antiviral Antiviral Research Center, 92131
    J Infect Dis 194:29-37. 2006
    ..Suboptimal CD4+ T cell recovery during antiretroviral therapy (ART) is a common clinical dilemma...
  7. ncbi Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression
    Miguel Goicoechea
    University California San Diego, School of Medicine, San Diego, California 92103, USA
    AIDS Patient Care STDS 20:233-7. 2006
    ..It should be recognized that not all patients are capable of achieving lifelong medication adherence and may benefit from continued supervised therapy...
  8. ncbi A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
    ..To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations...
  9. ncbi Efavirenz--still first-line king?
    Brookie M Best
    University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093 0719, USA
    Expert Opin Drug Metab Toxicol 4:965-72. 2008
    ..Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available...
  10. ncbi Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery
    Christopher H Woelk
    Department of Medicine, University of California, San Diego, La Jolla, USA
    AIDS 24:217-22. 2010
    ..To identify a pre-HAART gene expression signature in peripheral blood mononuclear cells (PBMCs) predictive of CD4 T-cell recovery during HAART in HIV-infected individuals...

Research Grants2

  1. Pharmacokinetics and Pathogenesis of Treatment Responses
    Miguel Goicoechea; Fiscal Year: 2007
    ..The projects proposed in this application are novel and will address important questions in HIV therapeutics. ..